RedHill Biopharma Ltd. (NASDAQ:RDHL) Sees Significant Growth in Short Interest

RedHill Biopharma Ltd. (NASDAQ:RDHL) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 34,000 shares, a growth of 486.2% from the February 13th total of 5,800 shares. Approximately 2.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 54,100 shares, the short-interest ratio is presently 0.6 days.

Institutional Trading of RedHill Biopharma

An institutional investor recently bought a new position in RedHill Biopharma stock. GAMMA Investing LLC acquired a new position in RedHill Biopharma Ltd. (NASDAQ:RDHL) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned about 0.40% of RedHill Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 7.20% of the company’s stock.

RedHill Biopharma Stock Performance

RDHL opened at $2.84 on Thursday. RedHill Biopharma has a 12-month low of $2.53 and a 12-month high of $20.28. The stock has a fifty day moving average of $5.21 and a 200-day moving average of $7.11.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on RedHill Biopharma in a research report on Thursday. They set a “hold” rating for the company.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.